---
title: "Tirabrutinib in Primary central nervous system lymphoma: Terms and abbreviations"
description: "Formulary evidence on Tirabrutinib in Primary central nervous system lymphoma: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/terms-and-abbreviations"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tirabrutinib in Primary central nervous system lymphoma: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| AAPC | Average annual percent change |
| ADR | Adverse drug reaction |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| AKT | Protein kinase B |
| ASCT | Autologous stem cell transplantation |
| ATC | Anatomical Therapeutic Chemical |
| AUC | Area under the concentration-time curve |
| BOR | Best overall response |
| BTK | Bruton tyrosine kinase |
| CAR-T | Chimeric antigen receptor T-cell |
| CAS | Chemical Abstracts Service |
| CD79B | Cluster of differentiation 79B |
| CI | Confidence interval |
| CLL | Chronic lymphocytic leukemia |
| CNS | Central nervous system |
| CR | Complete response |
| CRu | Unconfirmed complete response |
| CSF | Cerebrospinal fluid |
| CYP | Cytochrome P450 |
| DLBCL | Diffuse large B-cell lymphoma |
| DOR | Duration of response |
| EANO | European Association of Neuro-Oncology |
| ECOG | Eastern Cooperative Oncology Group |
| EHA | European Hematology Association |
| EORTC | European Organisation for Research and Treatment of Cancer |
| EQ-5D | EuroQol five-dimension questionnaire |
| ERK | Extracellular signal-regulated kinase |
| ESMO | European Society for Medical Oncology |
| FDA | Food and Drug Administration |
| HDC | High-dose chemotherapy |
| HD-MTX | High-dose methotrexate |
| HRQoL | Health-related quality of life |
| ILD | Interstitial lung disease |
| IPCG | International Primary CNS Lymphoma Collaborative Group |
| IRC | Independent review committee |
| JCOG | Japan Clinical Oncology Group |
| JPY | Japanese yen |
| KPS | Karnofsky Performance Status |
| MCL | Mantle cell lymphoma |
| MRI | Magnetic resonance imaging |
| MTR | Methotrexate, temozolomide, and rituximab |
| MTX | Methotrexate |
| MYD88 | Myeloid differentiation primary response 88 |
| NDA | New drug application |
| ORR | Overall response rate |
| OS | Overall survival |
| P-gp | P-glycoprotein |
| PBC | Primary biliary cholangitis |
| PCNSL | Primary central nervous system lymphoma |
| PDUFA | Prescription Drug User Fee Act |
| PFS | Progression-free survival |
| PK | Pharmacokinetics |
| PMDA | Pharmaceuticals and Medical Devices Agency |
| PR | Partial response |
| QoL | Quality of life |
| R-MPV | Rituximab, methotrexate, procarbazine, and vincristine |
| R/R | Relapsed or refractory |
| rwPFS | Real-world progression-free survival |
| SD | Stable disease |
| SJS | Stevens-Johnson syndrome |
| TEAE | Treatment-emergent adverse event |
| TEN | Toxic epidermal necrolysis |
| TIR | Tirabrutinib |
| TRAE | Treatment-related adverse event |
| TWD | New Taiwan dollar |
| USD | United States dollar |
| WBRT | Whole-brain radiotherapy |
| WM | Waldenström macroglobulinemia |

## Related pages
- [Tirabrutinib: Primary central nervous system lymphoma](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma.md)
- [Tirabrutinib: Primary central nervous system lymphoma](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/executive-summary.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Product information and disease description](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/product-information-and-disease-description.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Clinical evidence](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/clinical-evidence.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Economic information and modeling report](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/economics) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/economics.md)
- [Tirabrutinib in Primary central nervous system lymphoma: References](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/references) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/references.md)
- [Tirabrutinib in Primary central nervous system lymphoma: prevalence by geography](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/prevalence) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/prevalence.md)
- [Tirabrutinib in Primary central nervous system lymphoma: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/cost-effectiveness-analyses.md)
